Amgen stands by rare disease drug Tavneos amid Japan liver toxicity reportnews2026-05-18T18:21:35+00:00May 18th, 2026|Endpoints News|
The Supreme Court won’t take up drugmakers’ IRA casesnews2026-05-18T14:32:27+00:00May 18th, 2026|Endpoints News|
Regeneron’s Phase 3 skin cancer miss adds to mounting failures in LAG-3news2026-05-18T10:34:21+00:00May 18th, 2026|Endpoints News|
FDA approves AstraZeneca’s baxdrostat for certain patients with hypertensionnews2026-05-18T10:01:41+00:00May 18th, 2026|Endpoints News|
Biopharma M&A maintains strength even as large deals wanenews2026-05-15T17:56:32+00:00May 15th, 2026|Endpoints News|
Amgen expands crackdown on what it says is misuse of 340B programnews2026-05-15T17:31:40+00:00May 15th, 2026|Endpoints News|
Supreme Court preserves mail access for abortion pillnews2026-05-15T07:21:52+00:00May 15th, 2026|Endpoints News|
Drugmakers have to go through rigorous tests to get a lower tariff ratenews2026-05-14T16:00:16+00:00May 14th, 2026|Endpoints News|
AstraZeneca follows Merck with Phase 3 win in bladder cancernews2026-05-14T14:31:59+00:00May 14th, 2026|Endpoints News|
BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclextanews2026-05-14T10:31:51+00:00May 14th, 2026|Endpoints News|
